Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
Type:
Grant
Filed:
December 19, 2002
Date of Patent:
August 3, 2004
Assignee:
Wyeth
Inventors:
Derek Cecil Cole, Joseph Raymond Stock, William Joseph Lennox, Ping Zhou
Abstract: This invention relates to novel modified host cells which express heterologous fused proteins and methods of screening for test samples having peptide-binding activity; wherein the modified host cell comprises: (a) a gene sequence encoding a heterologous fusion protein; said fusion protein comprising a first peptide of a peptide binding pair, or segment of said first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; (b) a gene sequence encoding a heterologous fusion protein, said fusion protein comprising a second peptide of the peptide binding pair in (a), or a segment thereof, fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a); (c) a luciferase gene operatively associated with the transcriptional activation protein, or a portion thereof; (d) optionally, a deletion or mutation in the chromosomal DNA of the host cell for the transc
Abstract: This invention relates to a novel PTH gene. The invention further relates to methods of screening, diagnosis and development of therapies for bone related disorders.
Type:
Application
Filed:
November 10, 2003
Publication date:
July 29, 2004
Applicant:
Wyeth
Inventors:
John Allen Robinson, Vedrana Stojanovic-Susulic, Philip Babij, Richard John Murrills
Abstract: The present invention describes the identification of novel non-ribosomal peptide synthetases and associated biosynthetic genes from Streptomyces hygroscopicus. The present invention further provides methods for generating novel compounds, such as antibiotics, from these synthetases and associated genes.
Type:
Application
Filed:
December 23, 2003
Publication date:
July 29, 2004
Applicant:
Wyeth
Inventors:
John A. Hucul, Nathan Magarvey, Michael Greenstein
Abstract: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell.
Type:
Application
Filed:
February 13, 2004
Publication date:
July 29, 2004
Applicant:
Wyeth
Inventors:
Chandrasekhar Satishchandran, Catherine J. Pachuk
Abstract: This invention provides O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): 1
Type:
Application
Filed:
October 24, 2003
Publication date:
July 29, 2004
Applicant:
Wyeth
Inventors:
John P. Yardley, Magid A. Abou-Gharbia, John W. Ullrich
Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
Type:
Grant
Filed:
December 20, 2001
Date of Patent:
July 27, 2004
Assignee:
Wyeth
Inventors:
Ping Zhou, Derek Cecil Cole, Michael Gerard Kelly, William Joseph Lennox
Abstract: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
Type:
Application
Filed:
July 29, 2003
Publication date:
July 22, 2004
Applicant:
WYETH
Inventors:
Christopher John Corcoran, Carl R. Flannery, Weilan Zeng, Lisa A. Racie, Thomas McDonagh, Bethany A. Freeman, Katy E. Georgiadis, Edward R. LaVallie
Abstract: The present invention relates generally to the fields of neuroscience, growth factors and depression. More particularly, the present invention addresses the need in the art for methods and compositions for treating neurological disorders such as depression, anxiety, panic disorder, bi-polar disorder, insomnia, obsessive compulsive disorder, dysthymic disorder and schizophrenia. In certain embodiments, the invention relates to non-covalent binding interactions between insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs).
Type:
Application
Filed:
November 12, 2003
Publication date:
July 22, 2004
Applicant:
Wyeth
Inventors:
Christopher William Aston, Jessica Eden Malberg, Xavier Zafar Khawaja
Abstract: This invention provides compounds of formula I having the structure
wherein:
B, D, C, and R1 as defined herein.
Type:
Grant
Filed:
August 9, 2002
Date of Patent:
July 20, 2004
Assignee:
Wyeth
Inventors:
John A. Butera, Craig E. Caufield, Russell F. Graceffa, Alexander Greenfield, Eric G. Gundersen, Lisa Marie Havran, Alan H. Katz, Joseph R. Lennox, Scott C. Mayer, Robert E. McDevitt
Abstract: This disclosure describes antifungal antibiotics designated Hygroscopene A, Hygroscopene B and Hygroscopene C to their production by fermentation, to methods for recovery and concentration from the crude solutions, to a process for purification and to new analogs of Hygroscopene A, Hygroscopene B and Hygroscopene C prepared by synthetic procedures.
Type:
Application
Filed:
December 18, 2003
Publication date:
July 15, 2004
Applicant:
Wyeth Holdings Corporation
Inventors:
Ping Cai, Fangming Kong, Pamela Fink Charbonneau, Mark Edward Ruppen
Abstract: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell. In methods of treatment of prophylaxis of virus infections, other pathogenic infections or certain cancers.
Type:
Application
Filed:
February 6, 2004
Publication date:
July 15, 2004
Applicant:
Wyeth
Inventors:
Chandrasekhar Satishchandran, Catherine J. Pachuk
Abstract: A safe and effective process for the oxidation of a primary or secondary alcohol to the corresponding aldehyde or ketone via the reaction of said alcohol with an anhydride solution of a 1,1,1-tri(C2-C4 alkanoyloxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one, and a composition useful in this process.
Type:
Grant
Filed:
April 3, 2003
Date of Patent:
July 13, 2004
Assignee:
Wyeth
Inventors:
Ugo Chiacchio, Antonio Rescifina, Giuseppe Miraglia, Mariangela Magnano, Paola Di Raimondo
Abstract: Hydroxamic acids having the formula
are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
Abstract: The invention relates to new antibiotics designated Cyan-416A, Cyan 416B, Cyan-416C, Cyan-416D and Cyan-416E to their production by fermentation of Acremonium sp. NRRL 30631 to methods for recovery and concentration from the crude solutions, and to a process for purification and to semisynthetic ethers of Cyan-416B.
Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
Abstract: A vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain. The mutant immunogen lacks the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54. Reagent kits and assay methods help to distinguish vaccinated members of a poultry flock from those that may have been infected with wild-type Newcastle Disease virus.
Type:
Application
Filed:
December 2, 2003
Publication date:
July 8, 2004
Applicant:
Wyeth
Inventors:
Harmen J. Geerligs, Ian Hamer Brown, Dennis John Alexander, Michael Sinclair Collins